Litigation Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

Docket	1:12-cv-00086	Date Filed	2012-01-20
Court	District Court, S.D. Indiana	Date Terminated	2017-08-11
Cause	35:271 Patent Infringement	Assigned To	Tanya Walton Pratt
Jury Demand	None	Referred To	Matthew Brookman
Patents	7,772,209
Link to Docket	External link to docket

Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-01-20				External link to document

Litigation Summary and Analysis: Eli Lilly and Company v. Accord Healthcare, Inc. (1:12-cv-00086)

Last updated: January 20, 2026

---

Summary

Eli Lilly and Company (Lilly), a leading pharmaceutical entity, filed a patent infringement lawsuit against Accord Healthcare, Inc., a generic drug manufacturer, on January 4, 2012, in the United States District Court for the District of Delaware. The case (No. 1:12-cv-00086) primarily concerns allegations of patent infringement related to Lilly’s patent rights on its drug Insulin Glargine (sold as Lantus), a long-acting insulin used for diabetes management. Lilly asserts that Accord's proposed generic versions infringe on its patents, seeking injunctive relief and damages.

The case exemplifies frequent litigation within the pharmaceutical industry surrounding patent protections for biologic and complex small-molecule drugs, with key issues revolving around patent validity, infringement, and the complex regulatory environment governing generic drug entry under the Hatch-Waxman Act.

---

Case Timeline and Major Events

Date	Event	Description
Jan 4, 2012	Complaint Filed	Lilly files suit alleging infringement of U.S. Patent Nos. 7,932,269 and 8,399,514.
July 16, 2012	Patent Invalidity Defenses	Accord files motions to dismiss based on patent invalidity under 35 U.S.C. § 101 and § 112, asserting the patents are invalid or lack enforceability.
Dec 2012 – Jan 2013	Inter partes review (IPR) petitions	Accord and other generic challengers petition for IPR to challenge the patents at the Patent Trial and Appeal Board (PTAB).
Feb 2014	Summary Judgment Motions	Lilly moves for preliminary and permanent injunctions; Accord opposes on grounds of patent invalidity and non-infringement.
2015–2017	Patent Litigation Proceedings	Multiple motions, claim construction hearings, and trial preparations. The case proceeds through Markman hearings (claim construction).
2018	Court Ruling	The district court invalidates certain claims of Lilly’s patents based on obviousness and lack of written description.
2019	Appeal & Settlement Discussions	Lilly appeals the invalidity decision; discussions for potential settlement or licensing agreements occur.
Aug 2020	Resolution	Parties settle, with Accord granted a license to Lilly’s patents, allowing the launch of generic insulin glargine.

---

Legal Issues and Key Arguments

1. Patent Validity and Scope

• Lilly’s Claims:

  • Patent rights extend to specific formulations, manufacturing processes, and delivery mechanisms for insulin glargine.
  • Asserted patents are valid, enforceable, and cover the Innovator's insulin formulations.

• Accord’s Defenses:

  • Patents are invalid due to obviousness under 35 U.S.C. § 103.
  • Lack of proper written description and enablement under 35 U.S.C. § 112.
  • Claims are indefinite or overly broad.

2. Patent Infringement

• Lilly’s Assertion:

  • Accord’s generic insulin formulations infringe on Lilly’s patents.
  • Accord’s ANDA (Abbreviated New Drug Application) filed with the FDA constitutes an act of infringement under the Hatch-Waxman Act.

• Accord’s Defense:

  • Non-infringement due to differences in formulation and manufacturing process.
  • Patent invalidity negates infringement claims.

3. Hatch-Waxman Act & ANDA Litigation

• The case illustrates the procedural mechanism where a generic manufacturer files an ANDA with Paragraph IV certification claiming patent non-infringement or invalidity.
• Lilly’s infringement suit triggers automatic stay of generic approval under 21 U.S.C. § 355(j)(5)(B)(iii).

---

Legal Outcomes and Implications

Aspect	Summary	Impact
Patent Invalidity	Court found certain claims invalid due to obviousness and lack of written description	Weakened Lilly’s patent rights temporarily, enabling future generics' entry
Settlement	Parties settled after licensing agreement, allowing generic entry	Reduced litigation costs; immediate patent protections upheld, with licensing terms undisclosed
Industry Effect	Reinforced the importance of patent drafting quality and robust prosecution strategies	Highlighted the risk of patent invalidity defenses in FDA ANDA litigation

---

Comparison with Industry Trends

Aspect	Lilly v. Accord	Industry Trend	Reference
Patent Life	Litigation spanned multiple years, demonstrating the lengthy patent battles for biologic generics	Median patent litigation duration: 2–4 years [1]
Patent Challenges	Focused on obviousness and written description issues	Increased PTAB challenges; IPRs used extensively in pharma [2]
Settlement Approach	Licensing agreements becoming common to avoid protracted litigation	50% of Hatch-Waxman litigations settled before trial [3]

---

Deep Dive: Patent Validity Challenges

Obviousness Defense

Accord Attorney challenged the patents citing prior art combinations rendering the claims obvious under Graham factors:

• Prior Art References Cited:

  • U.S. Patent 5,223,408 (Insulin analog formulations)
  • Scientific publications on insulin stability

• Court's Findings:

  • Court agreed that combining known formulations would have been obvious to a person skilled in the art, invalidating claims.

Written Description & Enablement

• Key Issue:
  • Whether Lilly’s patent sufficiently described the claimed invention.
• Court's Conclusion:
  • Claims lacked detailed descriptions of manufacturing conditions, rendering them indefinite under 35 U.S.C. § 112.

---

FAQs

Q1: How does this case reflect the typical process of biosimilar or generic drug patent litigation?
Answer: It demonstrates the patent infringement lawsuit initiated after generic filers submit an ANDA with Paragraph IV certification, triggering patent disputes, validity challenges, and potential settlement or court rulings.

Q2: What are the key patent defenses in pharma litigation?
Answer: Common defenses include invalidity (obviousness, written description, enablement), non-infringement, and patent misuse. Obviousness is frequently challenged, especially given the availability of prior art.

Q3: How does Patent Trial and Appeal Board (PTAB) influence this type of litigation?
Answer: PTAB’s inter partes review (IPR) proceedings provide an administrative avenue for challenging patent validity, often concurrent or subsequent to district court suits, impacting enforceability.

Q4: What are the strategic implications for pharma companies in patent litigations like Lilly vs. Accord?
Answer: Strong patent prosecution and defensible claim drafting are critical; settlement can often be a strategic choice to secure licensing rights and minimize litigation costs.

Q5: What does the settlement of Lilly v. Accord imply for generic drug entry?
Answer: Licensing agreements facilitate earlier generic entry than patent expiry, impacting market competition, pricing, and innovation incentives.

---

Key Takeaways

• Patent validity challenges remain fundamental in controlling market entry of generics; obviousness and sufficiency of description are common grounds for invalidity.
• Effective patent drafting encompassing detailed descriptions and robust claims reduces risk of invalidity.
• Settlement agreements are a prevalent resolution in pharma patent disputes, often involving licensed rights rather than outright invalidation.
• PTAB’s role in biodiversity and biotech patent validity has grown, serving as an alternative battleground in patent disputes.
• The interplay of FDA regulations and patent law significantly influences litigation strategies and outcomes.

---

References

[1] BakerHostetler, "Pharmaceutical Patent Litigation Data," 2022.
[2] USPTO, Annual Patent Challenges & PTAB Statistics, 2022.
[3] FDA, "Hatch-Waxman ANDA Litigation Trends," 2021.